Ohtuvayre denied due to quantity / dose limits by Aetna?

Aetna's specific coverage criteria for ohtuvayre are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Applies Quantity Limits to Ohtuvayre

Ohtuvayre (ensifentrine) is dispensed as an inhalation suspension for use with a standard jet nebulizer. Aetna, like most insurers, applies quantity limits to brand inhalers and nebulized medications — restricting the number of vials, cartridges, or days' supply covered per fill or per period. A quantity-limit denial means your prescription as written exceeds the plan's approved supply limit. This does not mean the drug is inappropriate; it means the quantity submitted triggered an automated edit.

## Why This Denial Is Appealable

Quantity-limit denials are among the most commonly overturned on appeal when the prescribed quantity matches the FDA-approved dosing regimen:

• Internal appeal (ERISA §503 / ACA §2719): File a formal appeal requesting that the quantity limit be overridden to match the FDA-labeled dosing schedule. Plans must conduct a full-and-fair review.
• Quantity limit exception: Many plans have a separate exception pathway (faster than a full appeal) for quantities that align with the approved prescribing label. Ask specifically for this.
• External review (ACA §2719): After internal exhaustion or at 4 months from denial, an Independent Review Organization reviews the determination. The window is typically 4 months from the denial notice.
• Expedited option: Available if a standard timeline would seriously jeopardize your health.

## Documentation to Gather

1. FDA prescribing information: Print the dosing section of the FDA-approved prescribing label for Ohtuvayre from DailyMed. The label specifies the approved dosing frequency. If your prescribed quantity aligns with that schedule, document it explicitly. 2. Prescriber letter: A brief letter from your physician confirming that the prescribed quantity is consistent with the FDA-approved dosing regimen and is medically necessary to maintain treatment continuity. 3. Pharmacy records: If you have been stable on this medication, a dispensing history showing consistent use at the prescribed quantity supports medical necessity for the quantity requested. 4. Clinical need for supply duration: If you are requesting an extended supply (e.g., 90-day vs. 30-day), your prescriber should document why continuity of supply is clinically important (e.g., travel, remote location, therapy stability).

## Criteria-Mapping Structure

Obtain Aetna's published quantity limit table for Ohtuvayre (available through your pharmacy benefit manager or in the Clinical Policy Bulletin). Compare the limit to the FDA label dosing schedule. If the limit is less than what the label supports for your dosing frequency, state this explicitly in your appeal: "The FDA-approved dosing schedule for [approved indication] supports [frequency per label]. The prescribed quantity of [your quantity] is consistent with this schedule. The plan's limit of [plan limit] is below the labeled therapeutic supply."

## Next Step

Have your pharmacist call Aetna's pharmacy benefit line before filing a written appeal. Pharmacists can often resolve quantity limit edits through a peer-to-peer call or override request without a formal written appeal process.